Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1931-1939

  Heyman, Melvin B ^a   Kierkus, Jaroslaw ^b   Spénard, Jean ^c,d   Shbaklo, Hadia ^e   Giguere, Monique ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c Axcan Pharma Inc   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Formerly with Axcan Pharma   (Canada)

Author keywords

colitis; disease activity index; inflammatory bowel disease; mesalamine; pediatric patients; ulcerative proctitis

Indexed keywords

MESALAZINE;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; ARTICLE; BEDTIME DOSAGE; BLOOD ANALYSIS; BLOOD CHEMISTRY; BLOOD TRANSFUSION; BURNING SENSATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLONOSCOPY; DEFECATION; DEFECATION URGENCY; DIARRHEA; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; DRUG DOSAGE FORM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HEAT SENSATION; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCTITIS; RECTUM HEMORRHAGE; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SIGMOIDOSCOPY; STOOL FREQUENCY; SUPPOSITORY; ULCERATIVE COLITIS; ULCERATIVE PROCTITIS; UNSPECIFIED SIDE EFFECT; URINALYSIS; VOMITING; WELLBEING;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; PROCTITIS; SUPPOSITORIES; TREATMENT OUTCOME;

EID: 78249274931     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21256     Document Type: Article

References (43)

1. Kildebo S, Nordgaard K, Aronsen O, et al. The incidence of ulcerative colitis in Northern Norway from 1983 to 1986. The Northern Norwegian Gastroenterology Society. Scand J Gastroenterol. 1990; 25: 890-896.
2. Langholz E,. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull. 1999; 46: 400-415.
3. Miner PB Jr,. Clinical features, course, laboratory findings, and complications in ulcerative colitis. In:, Kirsner JB, ed. Inflammatory Bowel Disease. Philadelphia: W.B. Saunders; 2000.
4. Tysk C, Jarnerot G,. Ulcerative proctocolitis in Orebro, Sweden. A retrospective epidemiologic study, 1963-1987. Scand J Gastroenterol. 1992; 27: 945-950.
5. Marshall JK, Irvine EJ,. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000; 95: 1628-1636.
6. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006; 12: 972-978.
7. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006; 12: 979-994.
8. Jewel DP,. Ulcerative colitis. In:, Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease. Philadelphia: W.B. Saunders; 1993: 1305-1330.
9. Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001; 7: 221-225.
10. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000; 47: 410-414.
11. Gionchetti P, Venturi A, Rizzello F, et al. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther. 1997; 11: 679-684.
12. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis. 1990; 5: 79-81.
13. Farup PG, Hovde O, Halvorsen FA, et al. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 1995; 30: 164-170.
14. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998; 41: 93-97.
15. van Hogezand RA, van Hees PA, van Gorp JP, et al. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988; 2: 33-40.
16. Mamula P, Markowitz J, Baldassano R,. Clinical features and natural history of pediatric inflammatory diseases. In:, Sartor R, Sandborn W, eds. Kirsners Inflammatory Bowel Diseases. Philadelphia: WB Saunders; 2004: 555-565.
17. Grimm IS, Friedman LS,. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am. 1990; 19: 361-389.
18. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005; 146: 35-40.
19. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009; 58: 1490-1497.
20. Griffiths AM, Sherman PM,. Colonoscopic surveillance for cancer in ulcerative colitis: a critical review. J Pediatr Gastroenterol Nutr. 1997; 24: 202-210.
21. Kelsen J, Baldassano RN,. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis. 2008; 14: S9-S11.
22. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998; 43: 29-32.
23. Scott BB, Goodall A, Stephenson P, et al. Rectal mucosal plasma cells in inflammatory bowel disease. Gut. 1983; 24: 519-524.
24. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629.
25. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007; 13: 1244-1249.
26. Hawthorne AB, Rubin G, Ghosh S,. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008; 27: 1157-1166.
27. Moshkovska T, Stone M, Baker R, et al. Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 763-768.
28. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2933.
29. Shale MJ, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191-198.
30. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006; 51: 2165-2169.
31. Lakatos PL, Lakatos L,. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet? Pharmacol Res. 2008; 58: 190-195.
32. Robinson A,. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 27 (suppl 1): 9-14.
33. Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005; 11: 625-630.
34. Jaskowski TD, Litwin CM, Hill HR,. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin Vaccine Immunol. 2006; 13: 655-660.
35. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998; 42: 788-791.
36. Satsangi J, Landers CJ, Welsh KI, et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4: 18-26.
37. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohns disease. Am J Gastroenterol. 1998; 93: 1306-1310.
38. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohns disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004; 99: 2235-2241.
39. Marteau P, Florent C,. Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group. Am J Gastroenterol. 2000; 95: 166-170.
40. SALOFALK mesalamine suppository monograph. Axcan Pharma Inc.; 2004.
41. CANASA mesalamine suppository monograph. Axcan Pharma Inc.; 2008.
42. Cuffari C, Present DH, Bayless TM, et al. Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis. 2005; 11: 937-946.
43. Kirschner B,. The medical management of inflammatory bowel disease in children. In:, Kirsner JB, ed. Inflammatory Bowel Disease. Philadelphia: WB Saunders; 2000: 578-597.